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Abstract
There are gaps between recommendations on regular screening for diabetic kidney disease
(DKD) and clinical practice especially in busy and low resource settings. SUDOSCAN
(Impeto Medical, Paris, France) is a non-invasive technology for assessing sudomotor func-
tion using reverse iontophoresis and chronoamperometry which detects abnormal sweat
gland function. Vasculopathy and neuropathy share common risk factors and we hypothe-
sized that SUDOSCANmay be used to detect chronic kidney disease (CKD). Between
2012 and 2013, SUDOSCAN was performed in a consecutive cohort of 2833 Hong Kong
Chinese adults with type 2 diabetes. Chronic kidney disease was defined as estimated glo-
merular filtration rate <60 ml/min/1.73m2. In this cross-sectional cohort (mean age 58.6±9.5
years, 55.7%male, median disease duration 8 [interquartile range 3–14] years), 5.8% had
CKD. At a cut-off SUDOSCAN-DKD score of 53, the test had sensitivity of 76.7%, specificity
of 63.4% and positive likelihood ratio of 2.1 to detect CKD. The area under receiver operat-
ing characteristic curve for CKD was 0.75 (95% confidence interval 0.72–0.79). Patients
without CKD but low score had worse risk factors and complications than those with high
score. We conclude that SUDOSCANmay be used to detect patients at risk of impaired
renal function as part of a screening program in Chinese population, especially in outreach
or low resource settings.
Introduction
Diabetic kidney disease (DKD), indicated by albuminuria and/or reduced glomerular filtration
rate (GFR) predict end-stage renal disease, cardiovascular disease and all-cause mortality [1,2].
Due to its insidious nature and lack of overt symptoms until the advanced stages, regular labo-
ratory investigations are needed to detect DKD and its progression [3]. Major international
PLOSONE | DOI:10.1371/journal.pone.0134981 August 13, 2015 1 / 11
OPEN ACCESS
Citation: Luk AOY, Fu W-C, Li X, Ozaki R, Chung
HHY, Wong RYM, et al. (2015) The Clinical Utility of
SUDOSCAN in Chronic Kidney Disease in Chinese
Patients with Type 2 Diabetes. PLoS ONE 10(8):
e0134981. doi:10.1371/journal.pone.0134981
Editor: Muthuswamy Balasubramanyam, Madras
Diabetes Research Foundation, INDIA
Received: February 26, 2015
Accepted: July 15, 2015
Published: August 13, 2015
Copyright: © 2015 Luk et al. This is an open access
article distributed under the terms of the Creative
Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: All relevant data are
within the paper.
Funding: The study was supported by a research
grant by Impeto, Paris, France, and the Liao Wun Yuk
Diabetes Research Memorial Fund under the
Chinese University of Hong Kong. The Joint Asia
Diabetes Evaluation program was partly supported by
Merck Limited. Impeto, Paris, France, had input in
study design, manuscript revision and decision to
publish, but they had no role in data collection, data
analysis, and data interpretation. The other funders
including the Liao Wun Yuk Diabetes Research
Memorial Fund and Merck Limited had no role in
guidelines recommend screening for DKD on an annual basis by measuring serum creatinine
and urine albumin excretion [4]. With aggressive metabolic control and appropriate use of dis-
ease-modifying medications namely renin-angiotensin system (RAS) blockers, DKD is highly
treatable [5,6]. Yet, many patients are not screened due to poor disease awareness, costs of tests
and/or lack of infrastructure and personnel to support screening especially in low resource or
busy clinic settings [7]. Consequently, a reliable, convenient and non-invasive technology
which can identify subjects at risk of DKD may add value to these detection and preventive
strategies.
SUDOSCAN (Impeto Medical, Paris, France) is a novel technology that provides precise
evaluation of sudomotor function through reverse iontophoresis and chronoamperometry.
The technology enables measurement of electrochemical skin conductance based on reaction
between sweat chlorides and stainless-steel electrodes when low direct-current (DC) voltage is
applied [8]. A further advantage of the SUDOSCAN is that measurements are unaffected by
ambient heat or humidity [8]. Sweat glands are innervated by small unmyelinated sympathetic
C nerve fibers [9] and sudomotor dysfunction is known to occur during early stage of diabetes
and pre-diabetes [10]. The same device with different built-in algorithms (EZSCAN) has been
used to predict diabetes by evaluating early deficits in sudomotor function, and previous stud-
ies have reported association of electrochemical skin conductance with glycated hemoglobin
(HbA1c), fasting plasma glucose and 2-hour plasma glucose during oral glucose tolerance test
[11–15].
Since autonomic neuropathy reflects microvascular damage due to hyperglycemia and
related metabolic perturbation [16], the severity of sudomotor dysfunction may serve as a sur-
rogate for other microvascular complications including nephropathy. In a proof of concept
case-control study involving 50 Chinese patients with type 2 diabetes with renal complication
(estimated GFR<60 ml/min/1.73m2 and albuminuria) and 50, without, SUDOSCAN-DKD
score was highly correlated with GFR and albuminuria [17]. In the current study, we expanded
the sample size to evaluate the clinical utility of SUDOSCAN in detecting impaired renal func-




We enrolled patients from two diabetes centers in Hong Kong: the Diabetes and Endocrine
Centre at the Prince of Wales Hospital, and, the Yao Chung Kit Diabetes Assessment Centre
affiliated with the Chinese University of Hong Kong. Between 1st June 2012 and 31st October
2013, all Chinese adults aged18 years with type 2 diabetes who presented to either center for
assessment of diabetes complications, were invited to undergo additional evaluation using the
SUDOSCAN. Patients were excluded if they had type 1 diabetes (presentation with ketoacido-
sis or requiring insulin within a year of diagnosis), or had amputation of an arm or a leg. Refer-
ral sources for the centers included private and public hospital-based and community clinics,
as well as by self. All patients gave written informed consent and the study was approved by the
Joint Chinese University of Hong Kong—New Territories East Cluster Clinical Research Ethics
Committee. Declaration of Helsinki was adhered to.
SUDOSCAN
SUDOSCAN is a patented device designed to assess sudomotor function based on reverse ion-
tophoresis. This technology uses low DC stimulation to extract chloride ions from sweat to cre-
ate a current when these electrically charged ions encounter specific electrodes. The current
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produced is proportional to the chloride concentration that reacts with the electrodes, which in
turn reflects sweat gland function and its sympathetic innervation.
Four electrodes were placed on areas most enriched in sweat glands, namely the palmar
sides of hands and plantar sides of feet. A DC current at an incremental voltage of less than 4
volts was applied and the conductance (measured in μS), expressed as a ratio of the current
generated to the constant DC stimulus, was calculated for hands (left and right) and feet (left
and right). A time/ampere curve was recorded for each deviation and the mean value was esti-
mated for each area with low conductance correlating with high risk of sudomotor function
abnormality.
During the test, the patient placed his or her hands and feet on the electrodes. All electrodes
were connected to a computer for recording and data management. The test took 2 minutes to
perform, was painless, and no subject preparation was required. In addition, SUDOSCAN had
built-in algorithms which integrate electrochemical skin conductance with age to produce a
score that estimates current risks of CKD (SUDOSCAN-DKD score) [17].
Metabolic and Complication Assessment
All patients underwent clinical assessment as part of a quality improvement program using the
web-based Joint Asia Diabetes Evaluation (JADE) portal [18,19]. The latter contained built in
templates to guide comprehensive assessment of risk factors and diabetes complications fol-
lowed by automatic risk stratification, personalized reporting and decision support. Clinical
data included demographic, socio-economic and lifestyle factors as well as medical and family
history, BPs and anthropometric parameters including height, weight and waist circumference
were obtained using standard procedures. Fundi were assessed using retinal photography
through dilated pupils. Retinopathy was confirmed by the presence of dot and blot haemor-
rhages, hard exudates, cotton wool spots, neovascularization, laser scars, or a history of vitrec-
tomy. Peripheral sensory neuropathy was diagnosed by two of the three features: 1) reduced
sensation to monofilament in any part of the sole with normal skin; 2) a score of6/8 (age
younger than 65 years old) or4/8 (age older than 65 years old) using a 128-hertz graduated
tuning fork and 3) self-report of abnormal sensation in lower limbs. All assessments were car-
ried out by trained nurses while the interpretation of retinal photos was undertaken by diabe-
tologists. Cardiovascular disease was defined as history of coronary heart disease, stroke or
peripheral vascular disease, the latter defined as non-traumatic lower extremity amputation
and/or ankle:brachial ratio less than 0.9 by Doppler ultrasound scan.
Blood and urine samples were collected for plasma glucose, HbA1c, total cholesterol, low-
density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, triglycer-
ide, renal function test and urine albumin-to-creatinine ratio (ACR), after at least 8 hours of
fasting. Estimated GFR as expressed in ml/min/1.73m2 was calculated using the abbreviated
Modification of Diet in Renal Disease (MDRD) equation recalibrated for Chinese: estimated
GFR = 186×[SCR × 0.011] -1.154 × [age] -0.203 × [0.742 if female] ×1.233, where SCR was serum
creatinine in μmol/l and 1.233 was the adjusting coefficient for Chinese [20]. Chronic kidney
disease was defined as estimated GFR<60 ml/min/1.73m2. Microalbuminuria was defined as
urine ACR2.5–25.0 mg/mmol in men and3.5–25 in women, and macroalbuminuria, urine
ACR25.0 mg/mmol.
Statistical Analysis
The objectives of our initiative to evaluate the efficacy of SUDOSCAN in detecting and pre-
dicting CKD were set to firstly examine the association of SUDOSCAN-DKD score with esti-
mated GFR in a cross-sectional cohort, and at the next stage, to determine whether baseline
SUDOSCAN in Predicting Chronic Kidney Disease in Chinese
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SUDOSCAN-DKD score is associated with incident CKD in patients with normal renal func-
tion at baseline. We estimated the sample size based on expected incidence of CKD to enable
future prospective analysis. Assuming a correlation r value of 0.4 between estimated GFR and
SUDOSCAN-DKD score, 63 cases with CKD will give more than 95% power to confirm this
correlation. Assuming an annual incidence of CKD of 6.0%, 1900 patients would confirm
this incidence with 95% confidence interval of 5.0–7.2%. Assuming 30% of patients will not
be returning for repeat GFR at 1 year, we recruited over 2800 patients in the present cohort.
All data were expressed as mean±standard deviation (SD), median (inter-quartile range) or
percentages as appropriate. We used multiple linear regression to estimate the independent
correlation of SUDOSCAN-DKD score with estimated GFR adjusted for gender, disease dura-
tion, body mass index (BMI), systolic blood pressure (BP), HbA1c, LDL-cholesterol, use of RAS
blockers and use of other anti-hypertensive drugs. We did not adjust for age as age was already
included in the built-in calculation of the SUDOSCAN-DKD score. We constructed receiver
operating characteristic (ROC) curve to estimate the sensitivity and specificity of SUDOS-
CAN-DKD score for detecting CKD. The area under the ROC curve was calculated and the
optimal cut-point was the peak of the curve where the sum of sensitivity and specificity was
greatest. A 2-sided p-value<0.05 was considered significant. Statistical analysis was performed
using Statistical Package for Social Science software (version 2.0, Chicago, Illinois, USA).
Results
Clinical Characteristics
Amongst these 2833 patients with type 2 diabetes (mean age: 58.6±6.4 years, 55.7% male,
median duration of diabetes: 8 [inter-quartile range 3–14] years), 5.7% had CKD, 26.1% had
microalbuminuria and 9.9% had macroalbuminuria. The mean estimated GFR was 42.1±14.0
ml/min/1.73m2 in the CKD group and 116.0±28.1 ml/min/1.73m2 in the non-CKD group
(p = 0.001). Patients with CKD were older and had longer disease duration and worse meta-
bolic profile with higher BMI, systolic BP, HbA1c but lower blood haemoglobin (Table 1). They
were also more likely to have microvascular and macrovascular complications and be treated
with insulin, statins and RAS inhibitors.
Electrochemical skin conductance was lower in the CKD group than the non-CKD group at
both hands (42.9±22.1μS versus 54.6±22.5μS, p = 0.001) and feet (51.5±21.7μS versus 62.0
±18.6μS, p = 0.001). The mean SUDOSCAN-DKD score were 45.5±12.3 and 58.6±15.1 in the
CKD and non-CKD groups, respectively.
Correlation of SUDOSCAN-DKD Score with Estimated GFR
The scatterplot shows the relationship between SUDOSCAN-DKD score and estimated GFR
(Fig 1). On multiple linear regression, low SUDOSCAN-DKD score remained significantly
associated with low estimated GFR (β-coefficient 0.334, p<0.001), in addition to long disease
duration, male gender, high BMI, high systolic BP, low HbA1c, low LDL-cholesterol, and use of
anti-hypertensive drugs (Table 2). Low SUDOSCAN-DKD score was also independently asso-
ciated with high urine ACR although the magnitude of the correlation was small (β-coefficient
-0.054, p = 0.005).
Performance of SUDOSCAN in Detecting CKD
The area under the ROC curve of SUDOSCAN-DKD score to predict CKD was 0.75 (95%
confidence interval [CI] 0.72–0.79) of the total square (Fig 2). At SUDOSCAN-DKD score
cut-off of 53, the test had 76.7 (95% CI 69.4–82.9)% sensitivity and 63.4 (95% CI 61.5–65.2)%
SUDOSCAN in Predicting Chronic Kidney Disease in Chinese
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specificity to detect CKD with positive predictive value (PPV) of 0.11 (95% CI 0.10–0.13) and
negative predictive value (NPV) of 0.98 (95% CI 0.97–0.98). The likelihood ratio of a positive
test was 2.09 (95% CI 1.89–2.30), while the negative likelihood ratio was 0.37 (95% CI 0.26–
0.47). Using a higher SUDOSCAN-DKD score cut-off of 55 based on our group’s earlier analy-
sis of 100 diabetic patients [17], the sensitivity was increased to 81.0 (95% CI 74.1–86.7)%
while specificity was reduced to 57.9 (95% CI 56.0–59.8)%,
Table 1. Clinical characteristics of 2833 Chinese patients with type 2 diabetes stratified by presence of chronic kidney disease.
Patients with CKD (n = 163) Patients without CKD (n = 2670) p-value
Socio-demographics
Age (years) 66.9 ± 9.2 58.1 ± 10.4 <0.001
Male (%) 54.6 55.7 0.764
Current/ex-smoker (%) 27.0 29.0 0.576
Metabolic parameters
Disease duration (years) 15.8 ± 8.7 9.1 ± 7.2 <0.001
BMI (kg/m2) 27.1 ± 4.5 26.0 ± 4.3 0.004
Waist circumference (cm)
Male 94.1 ± 9.8 92.5 ± 10.3 0.140
Female 93.7 ± 13.0 88.1 ± 11.4 <0.001
Systolic BP (mmHg) 145.8 ± 19.3 132.1 ± 17.1 <0.001
Diastolic BP (mmHg) 78.1 ± 9.7 78.3 ± 9.9 0.791
HbA1c (%/mmol/mol) 7.8 ± 1.5 / 62 ± 11.9 7.4 ± 1.3 / 57 ± 10.0 <0.001
LDL-cholesterol (mmol/L) 2.2 ± 0.7 2.4 ± 0.8 0.003
HDL-cholesterol (mmol/L) 1.3 ± 0.4 1.3 ± 0.4 0.007
Triglyceride (mmol/L) 1.4 (1.1–2.0) 1.2 (0.9–1.8) 0.010
Haemoglobin (g/dL) 12.2 ± 1.9 13.7 ± 1.4 <0.001
Estimated GFR (ml/min/1.73m2) 42.1 ± 14.0 116.0 ± 28.1 0.004
Urine ACR (mg/mmol) 35.8 (7.6–180.8) 1.2 (0.5–4.1) 0.001
Diabetic complications
Microalbuminuria (%) 30.2 23.2 0.042
Macroalbuminuria (%) 56.2 7.1 <0.001
Diabetic retinopathy (%) 35.6 19.3 <0.001
Sensory neuropathy (%) 11.7 2.9 <0.001
Coronary heart disease (%) 17.8 9.7 <0.001
Medication use
ACE-inhibitors (%) 47.2 25.6 <0.001
ARB (%) 17.2 8.4 <0.001
Anti-hypertensive drugs (%) 71.8 40.8 <0.001
Statins (%) 58.3 38.2 <0.001
Insulin (%) 50.9 18.1 <0.001
SUDOSCAN
Hand ESC 42.9 ± 22.1 54.6 ± 22.5 <0.001
Foot ESC 51.5 ± 21.7 62.0 ± 18.6 <0.001
SUDOSCAN-DKD Score 45.5 ± 12.3 58.6 ± 15.1 <0.001
mean±standard deviation, median (inter-quartile range), or percentages as appropriate
ACE, angiotensin-converting enzyme; ACR, albumin-to-creatinine ratio; ARB, angiotensin receptor blockers; BMI, body mass index; BP, blood pressure;
CKD, chronic kidney disease; GFR, glomerular ﬁltration rate; ESC, electrochemical skin conductance; HbA1c, glycated haemoglobin; HDL, high density-
lipoprotein; LDL, low density-lipoprotein.
doi:10.1371/journal.pone.0134981.t001
SUDOSCAN in Predicting Chronic Kidney Disease in Chinese
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Patients without CKD but Low SUDOSCAN-DKD Score
Among patients with no CKD (n = 2670), 36.7% were scored53 on SUDOSCAN. Patients
with low score were older and more likely to be female with longer duration of diabetes than
those with score>53 (Table 3). These patients also had lower BMI, LDL-cholesterol, HbA1c,
blood haemoglobin, estimated GFR but higher systolic BP and were more likely to have micro-
albuminuria, retinopathy, sensory neuropathy and cardiovascular disease than those with high
score.
Fig 1. Scatterplot showing the relationship between SUDOSCAN-DKD score on y-axis and estimated
glomerular filtration rate on x-axis.
doi:10.1371/journal.pone.0134981.g001
Table 2. Clinical factors associated with estimated glomerular filtration rate in Chinese patients with
type 2 diabetes usingmultiple linear regression.
Standardβ-coefﬁcient P value
Female gender 0.132 <0.001
Disease duration -0.117 <0.001
BMI -0.051 0.003
HbA1c 0.049 0.004
Systolic BP -0.103 <0.001
LDL-cholesterol 0.018 0.288
Use of RAS blockers -0.030 0.097
Use of anti-hypertensive drugs -0.110 <0.001
SUDOSCAN-DKD score* 0.335 <0.001
BMI, body mass index; BP, blood pressure; HbA1c, glycated haemoglobin; LDL, low density-lipoprotein;
RAS, renin-angiotensin system
*SUDOSCAN-DKD score included age and electrochemical skin conductance
doi:10.1371/journal.pone.0134981.t002
SUDOSCAN in Predicting Chronic Kidney Disease in Chinese
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Discussion
Diabetic kidney disease is prevalent and requires periodic laboratory assessments to allow timely
intervention for cardiovascular-renal protection. In this large cross-sectional sample of commu-
nity-dwelling Chinese patients with type 2 diabetes, patients with a low SUDOSCAN-DKD
score (53) had 2-fold increased likelihood of having CKD than those with higher scores. Based
on our findings, we conclude that SUDOSCANmay be useful in detecting patients at risk of
having CKD. The worse risk factor and complications profiles in patients with normal GFR but
low SUDOSCAN-score suggested that the device might also have a utility in detecting early
renal involvement although prospective evaluation will be needed. Given the non-invasive and
portable nature of SUDOSCAN, it can be a used in outreach programs or low resource setting
as part of a CKD screening program.
Sudomotor function is a subtype of autonomic function which reflects the integrity of sym-
pathetic nerve fibers innervating the sweat glands [10]. Sudomotor dysfunction in diabetes is
manifested by attenuated sweat response to high ambient temperature and humidity espe-
cially in the lower peripheries [10]. With longstanding diabetes, chronic impairment of sudo-
motor function translates to reduced suppleness of skin, dryness and fissures especially in
their feet. The C fibers which innervate the sweat glands are typically long, thin and poorly
myelinated making them highly susceptible to damages by metabolic processes. The density
of nerve fibres innervating sweat gland based on skin biopsies has been shown to correlate
with measures of glycaemia including HbA1c in patients with diabetes [21]. Moreover, dam-
ages to these nerves may have occurred even before the onset of overt diabetes as supported
by reports of sudomotor dysfunction in subjects with impaired glucose tolerance and meta-
bolic syndrome [11–13,22].
Fig 2. Receiver operating characteristic curve of SUDOSCAN-DKD score in detecting chronic kidney
disease in Chinese patients with type 2 diabetes
doi:10.1371/journal.pone.0134981.g002
SUDOSCAN in Predicting Chronic Kidney Disease in Chinese
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Sudomotor function per se, however, is rarely measured in routine clinical practice as its
precise assessment is both time- and labor-consuming [23]. SUDOSCAN offers a rapid, easy,
non-invasive and validated tool to evaluate sudomotor function in a busy clinic setting. Given
the causal role of dysglycemia in impaired sudomotor function [11–13], other researchers have
used the same device with different built in algorithms (EZSCAN) to detect pre-diabetes in
European, Indian and Chinese populations [12–15].
Table 3. Clinical characteristics of patients without chronic kidney disease stratified by SUDOSCAN-DKD score of 53.
Patients with score  53 (n = 978) Patients with score > 53 (n = 1692) p-value
Socio-demographics
Age (years) 67.2 ± 6.7 52.9 ± 8.3 <0.001
Male (%) 52.1 57.9 0.005
Current/ex-smoker (%) 30.9 28.0 0.111
Metabolic parameters
Disease duration (years) 11.1 ± 8.0 8.0 ± 6.6 <0.001
BMI (kg/m2) 25.4 ± 4.0 26.4 ± 4.3 <0.001
Waist circumference (cm)
Male 91.6 ± 10.0 93.0 ± 10.4 0.011
Female 87.6 ± 10.6 88.4 ± 11.8 0.248
Systolic blood pressure (mmHg) 136.3 ± 17.6 129.6 ± 16.3 <0.001
Diastolic blood pressure (mmHg) 77.1 ± 9.8 78.9 ± 9.9 <0.001
HbA1c (%/mmol/mol) 7.3 ± 1.2 / 56 ± 9.2 7.5 ± 1.5 / 58 ± 11.6 0.001
LDL-cholesterol (mmol/L) 2.2 ± 0.7 2.5 ± 0.8 <0.001
HDL-cholesterol (mmol/L) 1.4 ± 0.4 1.3 ± 0.4 0.055
Triglyceride (mmol/L) 1.2 (0.9–1.6) 1.3 (0.9–1.8) 0.003
Haemoglobin (g/dL) 13.4 ± 1.4 13.9 ± 1.4 <0.001
Estimated GFR (ml/min/1.73m2) 105.4 ± 25.9 122.1 ± 27.6 <0.001
Urine ACR (mg/mmol) 1.5 (0.6–5.5) 1.1 (0.5–3.2) 0.001
Diabetic complications
Microalbuminuria (%) 28.8 24.0 <0.001
Macroalbuminuria (%) 8.4 6.4 0.059
Diabetic retinopathy (%) 23.4 20.3 <0.001
Sensory neuropathy (%) 4.5 2.0 <0.001
Coronary heart disease (%) 14.0 7.2 <0.001
Medication use
ACE-inhibitors (%) 26.7 25.0 0.336
ARB (%) 10.8 6.9 <0.001
Anti-hypertensive drugs (%) 53.5 37.5 <0.001
Statins (%) 41.5 36.2 0.007
Insulin (%) 17.8 18.3 0.761
SUDOSCAN
Hand ESC 43.4±21.3 61.0±20.6 <0.001
Foot ESC 49.6±18.5 69.1±14.5 <0.001
SUDOSCAN Score 43.5 ± 8.1 67.2 ± 10.8 <0.001
mean±standard deviation, median (inter-quartile range), or percentages as appropriate
ACE, angiotensin-converting enzyme; ACR, albumin-to-creatinine ratio; ARB, angiotensin receptor blockers; BMI, body mass index; GFR, glomerular
ﬁltration rate; ESC, electrochemical skin conductance; HbA1c, glycated haemoglobin; HDL, high density-lipoprotein; LDL, low density-lipoprotein.
doi:10.1371/journal.pone.0134981.t003
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Graded relationships between low electrochemical skin conductance measured by SUDOS-
CAN and severity of peripheral sensory neuropathy have been reported in people with diabetes
[24,25]. The use of SUDOSCAN to predict microvascular complications other than neuropathy
has also been explored in several small studies. From our group, analysis of 50 patients with
and 50 patients without DKD showed that electrochemical skin conductance was associated
with GFR independent of age, gender, disease duration, smoking, alcohol, BP, triglyceride,
hemoglobin, presence of other microvascular complications, and use of medications including
RAS inhibitors and anti-hypertensive agents [17]. Freedman and colleagues studied 390 Afri-
can and European Americans with type 2 diabetes and 166 controls and found independent
association between skin conductance and GFR (but not urine ACR) in African but not Euro-
pean Americans [26]. In the present cohort, we were able to confirm the independent associa-
tion between SUDOSCAN-DKD score and estimated GFR. Sudomotor dysfunction may have
similar pathogenic mechanisms to DKD. Processes downstream to sustained hyperglycaemia
including activation of protein kinase C, activation of the polyol pathway, and formation of
advanced glycosylation end products that are known to drive diabetic renal changes, have also
been implicated in causing reduction of endoneurial blood flow and direct nerve injury [27].
The natural progression of DKD involves the gradual transition from hyperfiltration to
albuminuria, to decline in GFR. While microalbuminuria is traditionally viewed as an early
indicator of diabetic renal involvement, its predictive value for advance renal disease is recently
challenged by poor sensitivity and specificity [28]. On the one hand, normoalbuminuria does
not preclude the presence of renal parenchymal changes and between 20–70% of patients may
progress to significant renal impairment while maintaining normoalbuminuria [28,29]. On the
other hand, albumin excretion may be increased in response to pathological or physiological
processes unrelated to diabetes such as posture, exercise, puberty, smoking, obesity, and infec-
tion. In addition, spontaneous remission of microalbuminuria has been observed in 20–60% of
patients without specific anti-proteinuric therapy [28]. The statistically significant but numeri-
cally small association between SUDOSCAN-DKD score and urine ACR in the present study
might be due to its single measurement with marked inter- and intra-individual variations.
The use of RAS inhibitors which have been shown to effectively lower urine ACR might also
have confounded the relationship between SUDOSCAN-DKD score with urine ACR.
In this analysis, the optimal SUDOSCAN-DKD score for detecting CKD was 53 with 77%
sensitivity and 63% specificity. In our previous case-control cohort, the cutoff value of 55 had
94% sensitivity and 78% specificity. The better performance might be due to greater case
dichotomization in our previous study [17]. While these subtle differences in performance
might be due to study design, selection criteria, sample size and ethnicity, the overall evidence
supports the clinical utility of SUDOSCAN in discriminating subjects with CKD.
We acknowledge the following limitations. One, despite the relatively large sample size of
this cross-sectional cohort, prospective evaluation is needed to confirm the clinical utility of
SUDOSCAN for risk stratification and prognostication in CKD. Two, only Chinese patients
were studied and our results might not be generalizable to other ethnic groups which might
have different patterns of risk attributes. Three, SUDOSCAN is a screening instrument only
and cannot replace blood and urine sampling for quantification of renal function.
Conclusion
In conclusion, SUDOSCAN may detect patients at high risk of CKD. Given its non-invasive,
portable and easy-to-use features, it may be used in outreach programs or low resource settings
as part of a detection program to identify high risk subjects for further assessments.
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